FDA, EMA Recommend Against Starting Olaratumab for Soft Tissue Sarcoma

January 24, 2019 – The FDA has recommended that no new patients with advanced soft tissue sarcoma (STS) should be treated with the combination of olaratumab plus doxorubicin, following the negative results of the phase III ANNOUNCE trial. The agency’s statement follows the January 2019 announcement that olaratumab in combination with doxorubicin missed the ANNOUNCE trial’s primary endpoint of overall survival (OS) and did not confirm a clinical benefit for … (leggi tutto)